Creation and Utilization of the Pharmaceutical Value Information Document in Japan

DOI
  • KAMAE Isao
    ealth Policy and Technology Assessment（ HPTA） Project, Graduate School of Public Policy, The University of Tokyo
  • FURUYAMA Naoki
    Japan Medical Office, Takeda Pharmaceutical Company Limited
  • FERNANDEZ Jovelle L.
    Japan Medical Office, Takeda Pharmaceutical Company Limited

Bibliographic Information

Other Title
  • 日本における医薬品の価値情報文書の作成及びその活用
  • Mock-up of Value Dossier
  • Value Dossierのモックアップ

Abstract

<p>Cost-effectiveness is an important indicator of the value of medicines, and is helpful when considering the acceptability of reimbursement decisions, or to set or adjust the prices of medicines in various countries. However, a multifaceted approach is needed to assess the value of medicines, and suitable criteria have so far been discussed mainly by international academic societies, taking into account the policies of individual countries. Here, we propose and explain the contents, composition, and preparation of the Pharmaceutical Value Information Document (abbreviated as value dossier), which has not yet been fully recognized in Japan. We take the case of a proton pump inhibitor as an example. The value dossier is expected to be a useful tool to clarify the value of medicines in actual clinical practice based on real-world evidence.</p>

Journal

Keywords

Details 詳細情報について

  • CRID
    1390574820807089792
  • DOI
    10.51018/pmdrs.53.4_322
  • ISSN
    24366226
    18846076
  • Text Lang
    ja
  • Data Source
    • JaLC
  • Abstract License Flag
    Allowed

Report a problem

Back to top